Successful combination therapy with trastuzumab and paclitaxel for adriamycin- and docetaxei-resistant inflammatory breast cancer

Breast Cancer

Volumn 11, Issue 3, 2004, Pages 309-312

  Okawa, Yutaka ^a   Sugiyama, Katsuki ^a   Aiba, Keisuke ^a   Hirano, Akio ^a   Uno, Shinji ^a   Hagino, Takeshi ^a   Kawase, Kazumi ^a   Shioya, Hisashi ^a   Yoshida, Kazuhiko ^a   Kobayashi, Masao ^a   Usui, Noriko ^a   Kobayashi, Tadashi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Inflammatory breast cancer; Paclitaxel; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DOXORUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; TAXOID; TRASTUZUMAB;

ARTICLE; BREAST TUMOR; CANCER STAGING; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; LEUKOPENIA; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURA EFFUSION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PLEURAL EFFUSION, MALIGNANT; TAXOIDS; TREATMENT OUTCOME;

EID: 16644393388     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02984555     Document Type: Article

References (23)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987. (Pubitemid 17231334)
2. Slamon D J, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989. (Pubitemid 19147683)
3. Hynes NE, Stern DF: The biology of erbB-2/neu/ HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184, 1994.
4. Ravdin PM, Charmness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review. Gene 159:19-27, 1995.
5. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289, 1992.
6. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ: Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-2249, 1998. (Pubitemid 28515376)
7. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Onco114:2197-2205, 1996. (Pubitemid 26264869)
8. Legha SS, Buzdar AU, Smith TL, Hortobagyi GN, Swenerton KD, Blumenschein GR, Gehan EA, Bodey GP, Freireich EJ: Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 91:847-852, 1979. (Pubitemid 10182656)
9. Pedrazzini A, Cavalli F, Brunner KW, Goldhirsch A, Mermillod B: Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. Oncology 44:51-59, 1987. (Pubitemid 17028393)
10. Jaiyesimi IA, Buzdar AU, Hortobagyi G: Inflammatory breast cancer: a review. J Clin Oncol 10:1014-1024, 1992.
11. Galmarini CM, Garbovesky C, Galmarini D, Galrnarini FC: Clinical Outcome and Prognosis of Patients with Inflammatory Breast Cancer. Am J Clin Oncol 25:172-177, 2002. (Pubitemid 34293072)
12. Kleer CG, van Golen KL, Merajver SD: Molecular biology of breast cancer metastasis inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Re 2:423-429, 2000. (Pubitemid 32223639)
13. D'Andrea GM, Seidman AD: Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects. Semin Oncol 24 (4 Suppl 13):1327-1344, 1997.
14. Itou Y, Hofikoshi N, Watanabe R: A phase II study of paclitaxel in patients with recurrent and/or advanced breast cancer 3-hour infusion. Shinyaku to Rinsho 46:476-486, 1997.
15. Ishitobi M, Shin E, Kikkawa N: Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxel. Int J Clin Oncol 6:55-58, 2001. (Pubitemid 32230365)
16. Pivot X, Asmar L, Hortobagyi GN: The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 15:381-386, 1999.
17. Katsumata K, Yamamoto K, Ashizawa T, Sumi T, Murohashi T, Katayanagi S, Kusama M, Koyanagi Y: Recurrent breast cancer successfully treated with a weekly dose of paclitaxel-a case report. Gan To Kagaku Ryoho 28:75-78, 2001.
18. Oura S, Tanino H, Yoshimatsu T, Sakurai T, Nakamura T, Kokawa Y, Matsuyama K, Naito Y: A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy. Gan To Kagaku Ryoho 28:511-514, 2001.
19. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for Treatment of human breast cancers. Oncogene 18:2241-2251, 1999. (Pubitemid 29186925)
20. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin TM) enhances the antitulnor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831, 1998. (Pubitemid 28311914)
21. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N EnglJMed 344:783-792, 2001. (Pubitemid 32222155)
22. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklafin N, Dickler M, D'Andrea G, Cristofanilli M, Pdvera E, Hortobagyi GN, Norton L, Hudis CA: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HELL2 inmunophenotype and gene amplification. J Clin Onco119:2587-2595, 2001. (Pubitemid 32441364)
23. Osoba D, Slamon DJ, Burchmore M, Murphy M: Effect on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Onco120:3106-3113, 2002. (Pubitemid 34791100)